Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis

Abstract only 89 Background: There is a lack of predictive markers informing on the risk of colitis in patients treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify potential factors associated with development of ICI colitis. Methods: We performed a retrospective...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 38; no. 5_suppl; p. 89
Main Authors Tyan, Kevin, Grover, Shilpa, Dougan, Michael, Sullivan, Ryan J., Giobbie-Hurder, Anita, Blum, Steven, Ishizuka, Jeffrey Joseph, Qazi, Taha, Elias, Rawad, Vora, Kruti, Ruan, Alex, Martin-Doyle, William, Eastman, Lauren, Davis, Meredith, Gargano, Maria, Haq, Rizwan, Buchbinder, Elizabeth Iannotti, Ott, Patrick Alexander, Hodi, F. Stephen, Rahma, Osama E.
Format Journal Article
LanguageEnglish
Published 10.02.2020
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract only 89 Background: There is a lack of predictive markers informing on the risk of colitis in patients treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify potential factors associated with development of ICI colitis. Methods: We performed a retrospective analysis of melanoma patients at Dana-Farber Cancer Institute who received PD-1, CTLA-4, or combination blockade between May 2011 to October 2017. Clinical and laboratory characteristics associated with pathologically confirmed ICI colitis were evaluated using multivariate logistic regression analyses. External validation was performed on an independent cohort from Massachusetts General Hospital. Results: The discovery cohort included 213 patients of whom 37 developed ICI colitis (17%). The odds of colitis were higher in patients treated with ipilimumab either as monotherapy or in combination with nivolumab compared to those treated with pembrolizumab. Vitamin D use was recorded in 66/213 patients (31%) before starting ICIs. In multivariable regression analysis, vitamin D use conferred significantly reduced odds of developing ICI colitis (OR 0.35, 95% CI 0.1–0.9). These results were confirmed in the validation cohort of 169 patients of whom 49 developed ICI colitis (29%). Pretreatment neutrophil/lymphocyte ratio (NLR) ≥5 predicted reduced odds of colitis (OR 0.34, 95% CI 0.1–0.9) only in the discovery cohort. Conclusions: This is the first study to report that among patients treated with ICIs, vitamin D intake is associated with reduced risk for ICI colitis. This finding is consistent with prior reports of prophylactic use of vitamin D in ulcerative colitis and GVHD. This observation should be validated prospectively in future studies. [Table: see text]
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.2020.38.5_suppl.89